Benitec Biopharma Limited（以下简称“Benitec Biopharma”）近日宣布，其针对BB-301的1B/2a期临床治疗研究摘要，已作为延迟突破性内容被肌肉萎缩症协会（MDA）临床与科学会议正式接受。这一进展标志着公司在推进基因疗法治疗肌肉萎缩症方面迈出了重要一步。
Benitec Biopharma Limited（以下简称“Benitec Biopharma”）近日宣布，其针对BB-301的1B/2a期临床治疗研究摘要，已作为延迟突破性内容被肌肉萎缩症协会（MDA）临床与科学会议正式接受。这一进展标志着公司在推进基因疗法治疗肌肉萎缩症方面迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.